Alnylam Pharmaceuticals (ALNY) Change in Cash (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Change in Cash for 18 consecutive years, with -$2.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Cash fell 103.14% year-over-year to -$2.9 million; the trailing twelve-month figure through Jun 2026 stood at $593.6 million (up 310.33% YoY), and the FY2025 full-year result was $690.2 million, up 348.83% from the prior year.
• Change in Cash retreated to -$2.9 million in Q2 2026 per ALNY's latest filing, from $53.6 million in the prior quarter.
• Across five years, Change in Cash topped out at $497.7 million in Q3 2022 and bottomed at -$285.9 million in Q1 2022.
• Historically, Change in Cash has averaged $49.3 million across 5 years, with a median of $47.5 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Change in Cash tumbled 144.27% in 2022, then jumped 2084.58% in 2024.
• Over 5 years, Change in Cash stood at -$206.8 million in 2022, then decreased by 6.52% to -$220.3 million in 2023, then jumped by 39.25% to -$133.8 million in 2024, then surged by 224.03% to $166.0 million in 2025, then plunged by 101.77% to -$2.9 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered -$2.9 million, $53.6 million, and $166.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.